Skip to content

Screening CEDM in Intermediate and High-Risk Patient Populations

Screening Contrast Enhanced Mammography (CEDM) in Intermediate and High-Risk Patient Populations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03859492
Enrollment
461
Registered
2019-03-01
Start date
2019-02-15
Completion date
2021-05-31
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This research study is being done to determine if Contrast Enhanced Digital Mammography (CEDM) can improve breast cancer detection and can be used as an additional screening method to the standard mammographic screening.

Interventions

High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Intervention model description

Patients are prospectively assigned to the CEDM /screening intervention which may lead to additional screening or biopsy based on the study schema.

Eligibility

Sex/Gender
FEMALE
Age
35 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women aged 35 and had a negative routine mammogram within 6 months. * Qualifies as intermediate or high-risk (\>15% lifetime risk of breast cancer as defined by IBIS version 8).

Exclusion criteria

* Known breast cancer * Previously had negative MBI or MRI within 12 months of study * Pregnant or lactating * Contraindication to intravenous iodinated contrast * Unable to understand or sign informed consent * Self-reported signs or symptoms of breast cancer

Design outcomes

Primary

MeasureTime frameDescription
Breast Cancer3 yearsNumber of subjects diagnosed with breast cancer

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026